Find Funding Opportunities

The purpose of this FOA is to support the Neuroscience Information Framework Infrastructure and Search for Lacunas/Gaps in Knowledge About the Nervous System.

This Funding Opportunity Announcement (FOA) invites applications to build on the data collected using the very well defined experimental protocols of the Human Connectome Project (HCP) (http://www.neuroscienceblueprint.nih.gov/connectome/). Applications are sought that will apply the Human Connectome data collection protocol to disease/disorder cohorts of interest to the Institutes and Centers that are participating in this FOA. These cohorts will be defined by the applicant and can include subjects with specific symptoms or conditions, with comorbid conditions, with a specific genetic profile, or other applicant defined criteria.

The objective of the NIH Career Transition Award (K22) is to provide support to outstanding basic or clinical investigators to develop their independent research skills through a two phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.

This Funding Opportunity Announcement (FOA) encourages Research Project Grant (R01) applications from institutions/ organizations that propose research relevant to the basic understanding and development of therapeutic interventions for currently screened conditions and high priority genetic conditions for which screening could be possible in the near future.In this FOA, a high priority condition is one for which the development of an efficacious therapy would make the condition amenable to newborn screening.

The purpose of this funding opportunity announcement (FOA) is to encourage exploratory clinical trial applications to the newly authorized Direct-to-Phase II SBIR grant mechanism.The projects must focus on products related to the mission and goals of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Applications are invited from eligible United States small business concerns (SBCs) that have demonstrated the scientific and technical merit and feasibility of the prototype stage of developing a biomedical technology that has commercial potential, RandD that is characteristic of Phase-I (R43) SBIR projects.The Direct-to-Phase II grant mechanism is intended to facilitate SBIR-type RandD, to expand RandD opportunities for applicant small business concerns (SBCs), and to enhance the pace of technology development and commercialization.

The National Institutes of Health (NIH), through its Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products and services that benefit society.Toward meeting this objective, the NIH is collaborating with the National Science Foundation (NSF) to help accelerate the commercialization of early stage biomedical technologies by leveraging the NSF's established I-Corps team training program, which is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace.Under this funding opportunity announcement (FOA), participating NIH Institutes and Centers will provide administrative supplement awards to a pilot cohort of currently-funded SBIR and STTR Phase I grantees to support entrepreneurial training under the I-Corps Team Training Pilot Program at the NIH.The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH SBIR and STTR funding.It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies.Prospective applicants are strongly encouraged to contact NIH Scientific/Research staff for more information about this pilot program before applying.

The purpose of this funding opportunity announcement (FOA) is to support up to three years of study for the discovery, assay optimization, and replication stages required for the development of biological biomarkers for Parkinsons disease (PD).It is expected that studies funded under this FOA will integrate with and enhance the NINDS Parkinson's Disease Biomarker Program (PDBP). Discovery or pilot projects may use samples from either the PDBP or otherextant biospecimens and data, as long as consent for the extant biospecimens and data enables deposition of all data into the PDBP Data Management Resource (DMR). It is expected that the replication stage study will use PDBP biospecimensand data.This FOA is only for studies related to human biomarkers; animal or other disease model studies are not appropriate for this FOA. A timeline including milestones is required for all studies. Annual milestones will provide clear indicators of a project's continued success or emergent difficulties and will be used to evaluate the application not only in peer review but also in consideration of the awarded project for funding of non-competing award years.

This Funding Opportunity Announcement (FOA) invites applications from investigators to participate in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLAGC), formerly the HLA Region Genomics in Immune-Mediated Diseases Consortium. This cooperative research group supports projects defining the association between variations in the human leukocyte antigen (HLA), also known as the Major Histocompatibility Complex (MHC), and natural killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and organ transplantation.

This Funding Opportunity Announcement (FOA) invites applications from investigators to participate in the HLA and KIR Region Genomics in Immune Mediated Diseases Consortium (HLAGC), formerly the HLA Region Genomics in Immune-Mediated Diseases Consortium.This cooperative research group supports projects defining the association between variations in the human leukocyte antigen (HLA), also known as the Major Histocompatibility Complex (MHC), and natural killer cell immunoglobulin-like receptor (KIR) genetic regions and immune-mediated diseases, including outcomes following cell, tissue, and organ transplantation.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery. The program will utilize the cooperative agreement mechanism to enable milestone-drive projects. Successful applicants may be given access to the NIH StrokeNet infrastructure. Following peer review, NINDS will prioritize trials among the highest scoring to be given access to the StrokeNet infrastructure. The StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently. The StrokeNet National Data Management Center (NDMC) will provide statistical and data management support. The Regional Coordinating Centers (RCCs) of the StrokeNet and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. The StrokeNet network will also be uniquely poised to collaborate with the NINDS Neurological Emergencies Treatment Trials Network (NETT) and/or other US and international consortia necessary to conduct larger, definitive trials of promising interventions for stroke treatment, prevention, and recovery.